Loading
Two years of an antibody given every two months after first-line chemotherapy raised the proportion still free of progression at three years from 58 to 75 per cent.
An open-label randomised trial at 223 centres in 25 countries. 1,217 patients with previously untreated follicular lymphoma needing systemic therapy received one of three non-randomised immunochemotherapy induction regimens used in routine practice, and the 1,019 who achieved a complete or partial response were randomised to rituximab 375 mg per square metre every eight weeks for two years or to observation.
505 patients were assigned to maintenance and 513 to observation (one died during randomisation). With a median follow-up of 36 months, progression-free survival was 74.9 per cent (95 per cent confidence interval 70.9 to 78.9) with maintenance, with 130 progressions, against 57.6 per cent (53.2 to 62.0) with observation, with 218 progressions: hazard ratio 0.55 (0.44 to 0.68).
The trial that made two years of rituximab maintenance a routine offer after first-line immunochemotherapy for follicular lymphoma with a high tumour burden.
Shares Gilles Salles, Maintenance and consolidation in lymphoma: where it works and where it does not, LYSA (The Lymphoma Study Association), Maintenance therapy and the tag lymphoma-evidence.
Shares Gilles Salles, Maintenance and consolidation in lymphoma: where it works and where it does not, LYSA (The Lymphoma Study Association), Maintenance therapy and the tag lymphoma-evidence.
Shares Maintenance and consolidation in lymphoma: where it works and where it does not, Maintenance therapy, CD20, Rituximab and the tag lymphoma-evidence.
Shares LYSA (The Lymphoma Study Association), Maintenance therapy, CD20, Rituximab and the tag lymphoma-evidence.
Shares Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study, FLIPI, FLIPI2 and POD24 (follicular lymphoma risk), Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares FLIPI, FLIPI2 and POD24 (follicular lymphoma risk), CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares Maintenance and consolidation in lymphoma: where it works and where it does not, Maintenance therapy, CD20, Rituximab and the tag lymphoma-evidence.
Shares CD20, The Lancet, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.